Tags : Lucid Diagnostics

PharmaShots Weekly Snapshot (March 02-06, 2020)

1. Mount Sinai Signs a Multi-Year Collaboration with Harbour BioMed to Develop Novel Biotherapies for Multiple Cancer Indications and COVID-19 Published: Mar 06, 2020 | Tags: Mount Sinai, Signs, Multi-Year, Collaboration, Harbour BioMed, Develop, Novel Biotherapies, Multiple Cancer Indications, COVID-19 2. AstraZeneca Reports Results of Imfinzi and Tremelimumab in P-III DANUBE Study for Unresectable Stage IV […]Read More

Lucid Diagnostics Collaborates with the University of Pennsylvania to Evaluate

Shots: The Lucid-Penn agreement will evaluate Lucid’s EsoCheck esophageal cell collection device with Collect+Protect technology as a less invasive, more efficient, and cost-effective alternative to endoscopic biopsies to manage patients with EoE The study will assess 10 patients with suspected or established EoE scheduled for a clinically indicated upper endoscopy which will undergo esophageal sampling […]Read More